Triggering tumor immunity through angiogenesis targeting.
Jinushi
Masahisa
M
Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institutel, Boston, Massachusetts 02115, USA.
Dranoff
Glenn
G
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008495:Medical Oncology / Q000379:methods; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology* / Q000628:therapy*; D009389:Neovascularization, Pathologic
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents